Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 39

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
56 — — — 1,364 — — 1,364 Stock-based compensation— — — — 12,524 — — 12,524 Purchase of treasury stock, inclusive of excise tax— (837)— (25,121)— — — (25,121)Purchase of capped call transaction, net of tax— — — — (20,112)— — (20,112)Other comprehensive loss (Note 11)— — — — — — (47)(47)Net income— — — — — 18,886 — 18,886 Balance at June 30, 202446,954 (837)$47 $(25,121)$983,178 $(78,931)$105 $879,278 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 7

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(In thousands)

(Unaudited)

 Number of Shares OutstandingAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome  Common SharesTreasury SharesCommon StockTreasury StockTotalBalance at December 31, 202447,078 (837)$47 $(25,121)$1,009,435 $(206,356)$343 $778,348 Vested restricted stock units722 — 1 — 1 — — 2 Common stock withheld for employee withholding tax liabilities on vested restricted stock units(210)— — — (5,467)— — (5,467)Common stock issued under employee stockpurchase plan101 — — — 1,569 — — 1,569 Stock-based compensation— — — — 30,025 — — 30,025 Purchase of treasury stock, inclusive of excise tax and broker fees— (1,956)— (50,394)— — — (50,394)Other comprehensive income (Note 11)— — — —